- Home
- IGMS vs BW Comparison
IGMS vs BW Comparison
Compare IGMS & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- BW
- Stock Information
- Founded
- IGMS 1993
- BW 1867
- Country
- IGMS United States
- BW United States
- Employees
- IGMS N/A
- BW N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- BW Building Products
- Sector
- IGMS Health Care
- BW Industrials
- Exchange
- IGMS Nasdaq
- BW Nasdaq
- Market Cap
- IGMS 81.9M
- BW 95.7M
- IPO Year
- IGMS 2019
- BW N/A
- Fundamental
- Price
- IGMS $1.27
- BW $1.04
- Analyst Decision
- IGMS Hold
- BW Strong Buy
- Analyst Count
- IGMS 8
- BW 1
- Target Price
- IGMS $6.00
- BW $5.00
- AVG Volume (30 Days)
- IGMS 1.3M
- BW 865.1K
- Earning Date
- IGMS 08-13-2025
- BW 08-07-2025
- Dividend Yield
- IGMS N/A
- BW N/A
- EPS Growth
- IGMS N/A
- BW N/A
- EPS
- IGMS N/A
- BW N/A
- Revenue
- IGMS $2,681,000.00
- BW $734,239,000.00
- Revenue This Year
- IGMS $252.44
- BW $5.81
- Revenue Next Year
- IGMS $46.48
- BW $9.24
- P/E Ratio
- IGMS N/A
- BW N/A
- Revenue Growth
- IGMS 27.36
- BW 12.90
- 52 Week Low
- IGMS $0.92
- BW $0.22
- 52 Week High
- IGMS $22.50
- BW $2.99
- Technical
- Relative Strength Index (RSI)
- IGMS 48.73
- BW 53.47
- Support Level
- IGMS $1.26
- BW $0.97
- Resistance Level
- IGMS $1.37
- BW $1.10
- Average True Range (ATR)
- IGMS 0.03
- BW 0.06
- MACD
- IGMS -0.01
- BW -0.00
- Stochastic Oscillator
- IGMS 8.33
- BW 49.64
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About BW Babcock & Wilcox Enterprises Inc.
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.